Keyword: Versant Ventures
Gotham Therapeutics has raised $54 million to advance small-molecule inhibitors of mRNA-modifying proteins as far as clinical proof of concept.
Coda Biotherapeutics' goal is to create a gene therapy that can be switched on and off, and dialed up and down.
Akero Therapeutics raised $65 million to advance its lead program, a FGF21 analog, for the treatment of NASH.
The cash equips Lava to advance bispecific engagers of γδ T cells, a small subgroup of lymphocytes involved in natural and induced immunity to cancer.
The financing tees up Enterprise to take three projects into the clinic and push one of them through a midphase proof-of-concept trial.
Roche snapped up a remyelinating drug candidate for multiple sclerosis from an alliance with Versant that also spawned startup Pipeline Therapeutics.
With Inari's commercial opportunities increasing, it has pulled in its biggest round to date to fuel a sales and marketing push.
The four-year alliance tasks Vividion with discovering drugs that interact with the ubiquitin proteasome system cells used to break proteins apart.
The funding will see Quentis' lead immunotherapy candidate into the clinic in 2019.
Pandion Therapeutics is working on localized treatments for autoimmune and inflammatory disease.